NCT00562952 (PONTIAC) is a Phase 2/Phase 3 clinical trial of Telmisartan, Bisoprolol in Diabetes Mellitus, sponsored by Medical University of Vienna.

Who is sponsoring NCT00562952?

NCT00562952 is sponsored by Medical University of Vienna.

What drugs are being tested in NCT00562952?

Interventions in NCT00562952: Telmisartan, Bisoprolol, placebo.

What condition does NCT00562952 study?

NCT00562952 studies Diabetes Mellitus, Heart Failure, Coronary Artery Disease.

Is NCT00562952 still recruiting?

NCT00562952 is currently completed. Last updated 2 May 2012.

Last reviewed 2012-05-02 · How we verify

NCT00562952: PONTIAC

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Nt-proBNP Guided Prevention of Cardiovascular Events in a Population of Diabetic Patients Without a History of Cardiac Disease

Completed Phase 2/Phase 3 Last updated 2 May 2012

What this trial tests

Phase 2/Phase 3 trial testing Telmisartan, Bisoprolol in Diabetes Mellitus in 300 participants. Completed in 1 December 2011.

Timeline

1 November 2007

Primary endpoint
1 December 2011

1 December 2011

Quick facts

Lead sponsor	Medical University of Vienna
Phase	Phase 2/Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	prevention
Enrollment	300
Start date	1 November 2007
Primary completion	1 December 2011
Estimated completion	1 December 2011
Sites	2 locations across Austria

Drugs / interventions tested

Telmisartan, Bisoprolol — full drug profile →
placebo

Conditions studied

Diabetes Mellitus — all drugs for Diabetes Mellitus →
Heart Failure — all drugs for Heart Failure →
Coronary Artery Disease — all drugs for Coronary Artery Disease →

Sponsor

Medical University of Vienna

Who can join

Adults 19 to 95, any sex, with Diabetes Mellitus or Heart Failure. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Reduction in cardiac events
Time frame: 2

Sponsor's own description

Increased levels of NT-proBNP are known to increase the risk of cardiac events in diabetic patients. The other way around, patients with normal values have an excellent prognosis on short-term. We intend in our study to proof the hypothesis, whether it is possible to decrease NT-proBNP levels by intensified cardiac prevention care We aim those patients, who already have elevated levels, although no history of a cardiac disease. This decrease in NT-proBNP should be translated consequently in a decrease in cardiac events

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

PONTIAC (NT-proBNP selected prevention of cardiac events in a population of diabetic patients without a history of cardiac disease): a prospective randomized controlled trial.
Huelsmann M, Neuhold S, Resl M, Strunk G, et al · · 2013 · cited 252× · PMID 23810874 · DOI 10.1016/j.jacc.2013.05.069

Verify or expand the search:

Other recruiting trials for Diabetes Mellitus

Currently open trials in the same condition.

NCT07238556 — A Novel Digital Tool Physicians Can Use to Prescribe Exercise to Patients With Cardiovascular Disease Risk Factors · NA · recruiting
NCT07392437 — Prevalence of Diabetes-related Distress Among Patients Living With Type 2 Diabetes in a University Hospital Center and I · NA · recruiting
NCT07448805 — Accuracy and Safety of the Syai Tag System for Continuous Glucose Monitoring in Intensive Internal Care Unit · NA · recruiting
NCT07425275 — Integrated Oral Care Intervention for Xerostomia in Diabetes Patients · NA · recruiting
NCT06918977 — Improving Glycemic Control With Telemedicine and Smart Insulin Pens · NA · recruiting

Other Medical University of Vienna trials

Trials by the same sponsor.

NCT07473401 — Retinal Oxygen Metabolism in Children With Myopia · not yet recruiting
NCT07511400 — The Role of NaV1.8 in Human Pain Models · EARLY_PHASE1 · not yet recruiting
NCT07516990 — Intramuscular Injection of Mashed Parathyroid Tissue Into a Forearm During Thyroid Surgery to Prevent Permanent Postoper · NA · recruiting
NCT07496437 — Is Cross-linked Hyaluronic Acid a Biologic Alternative for Alveolar Ridge Preservation? · NA · not yet recruiting
NCT07290712 — Post-Intensive Care Syndrome - Multicentre Prospective Registry Database of the DACH Region · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00562952 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Medical University of Vienna
Last refreshed: 2 May 2012

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00562952.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing